Biotech Leader BeOne Medicines Poised To Hit Early Buy Points
Biotech leader BeOne stock is poised to hit multiple buy points. Its blockbuster drug generated $1.2 billion in sales in the second quarter. Continue Reading
YENOM NOTICIAS
Qué está moviendo el mercado.
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
BeOne Medicines (ONC) Stock May Be Fully Priced After An 86% Run
BeOne Medicines has delivered an 86.0% gain over the past three years, yet current valuation checks point to a stock that screens as overvalued on market multiples and only mixed on broader metrics. Recent regulatory wins and a higher shar…
The Bull Case For BeOne Medicines (ONC) Could Change Following US-Backed HER2 Regimen And Onshoring Deal
BeOne Medicines recently secured U.S. FDA approvals for TEVIMBRA and ZIIHERA-based regimens in first-line HER2-positive gastroesophageal cancers and entered a voluntary agreement with the U.S. government to expand access to its oncology dr…
BeOne (ONC) Secured a Pharmaceutical-Tariff Exemption After More than $1B of U.S. Manufacturing Investment. Are the Pricing Concessions Worth It?
BeOne Medicines AG (NASDAQ:ONC) entered a voluntary agreement with the U.S. government that combines pharmaceutical-tariff protection with commitments on manufacturing, Medicaid participation, and the pricing of future medicines. The agree…
FDA Approval Marks A Turning Point For BeOne Medicines (ONC)
On August 25, BeOne Medicines (NASDAQ:ONC) said the FDA approved TEVIMBRA in combination with ZIIHERA and chemotherapy as a first-line treatment for HER2-positive gastroesophageal adenocarcinoma, a hard-to-treat cancer that strikes more th…
Trump's MFN Push Goes Beyond Big Pharma, Adds 9 Mid-Sized Drugmakers
On Monday, President Trump announced that his administration has signed separate drug-pricing agreements with nine mid-sized pharmaceutical companies to lower drug prices in the country. These companies include Alcon, Astellas Pharma ALPMY…
BeOne Medicines to Present at the Morgan Stanley Annual Global Healthcare Conference
SAN CARLOS, Calif., September 01, 2026--(BUSINESS WIRE)--BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced it will participate in the Morgan Stanley Annual Global Healthcare Conference…
BeOne Medicines Announces Voluntary Agreement with U.S. Government to Expand Access to Innovative Cancer Medicines
Agreement advances patient access and strengthens BeOne's long-term commitment to U.S. innovation and manufacturing SAN CARLOS, Calif., August 31, 2026--(BUSINESS WIRE)--BeOne Medicines, Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a glob…
BeOne Medicines Announces New Phase 3 Survival Data Reinforcing Benefit of ZIIHERA-Containing Regimens in First-Line HER2+ Gastroesophageal Cancer
Findings provide further evidence of overall survival benefit of TEVIMBRA plus ZIIHERA and chemotherapy regimen in HER2+ GEA ZIIHERA plus chemotherapy demonstrated statistically significant overall survival benefit at second interim analys…
Generative "AI" Macro Data Shows U.S. Impacts
Time now for some fresh generative "AI" data and insight from FRED. Here to help us interpret it is our Chief Equity Strategist and Economist, John Blank. 1. For those who don't know, what is FRED? 2. What is the new data? 3. What does it…
BeOne Medicines Ltd. - Sponsored ADR (ONC) is a Great Momentum Stock: Should You Buy?
Momentum investing is all about the idea of following a stock's recent trend, which can be in either direction. In the "long context," investors will essentially be "buying high, but hoping to sell even higher." And for investors following…
BeOne Medicines Announces U.S. FDA Approval for TEVIMBRA-Based Regimen for First-Line HER2+ GEA
TEVIMBRA plus ZIIHERA and chemotherapy is the first and only immunotherapy-based regimen to deliver more than two years of median OS in first-line HER2+ GEA, regardless of PD-L1 status Regimen poised to become standard of care in this diff…
BeOne Medicines Ltd. - Sponsored ADR (ONC) Now Trades Above Golden Cross: Time to Buy?
BeOne Medicines Ltd. - Sponsored ADR (ONC) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, ONC's 50-day simple moving average broke out above its 200-day moving average; t…
BeOne Medicines, BeOne Care Foundation, and The Max Foundation Renew Partnership to Expand Access to BRUKINSA® for the Treatment of Chronic Lymphocytic Leukemia in Low- and Middle-Income Countries
Renewed collaboration builds on access provided to more than 300 patients with CLL to date and plans to support approximately 1,000 patients through 2028 SAN CARLOS, Calif. & SEATTLE, August 18, 2026--(BUSINESS WIRE)--BeOne Medicines Ltd.…
Is BeOne Medicines AG (ONC) Deal With Revolution Medicines (RVMD) a Win-Win for Both Companies?
Two oncology powerhouses, BeOne Medicines AG (NASDAQ:ONC) and Revolution Medicines, Inc. (NASDAQ:RVMD), announced a major multi-part clinical collaboration and regional licensing deal. Under the August 10 agreement, the companies will comb…
BeOne Medicines Ltd (ONC) (Q2 2026) Earnings Call Highlights: Revenue Surges 30% to $1. ...
This article first appeared on GuruFocus. Total Revenue: $1.7 billion, representing 30% growth year over year. GAAP Earnings per ADS: $2.05, up 144% compared to the prior year. BRUKINSA Global Revenue: Over $1.2 billion, representing 31% y…
BeOne Medicines and Revolution Medicines Announce Clinical Development and Regional Commercialization Collaboration
Clinical collaboration enables novel combinations of select BeOne oncology assets with four Revolution Medicines clinical-stage RAS(ON) inhibitors for RAS-addicted cancers Regional rights agreement provides BeOne with exclusive development…
Is BeOne Medicines (ONC) Undervalued Following Its Earnings Beat And Raised Outlook?
Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. BeOne Medicines (ONC) is back in focus after reporting second quarter 2026 results on 5 August, with revenue and earnings su…
BeOne Medicines Ltd. - Sponsored ADR (ONC) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates
BeOne Medicines Ltd. - Sponsored ADR (ONC) reported $1.71 billion in revenue for the quarter ended June 2026, representing a year-over-year increase of 29.6%. EPS of $2.05 for the same period compares to $0.84 a year ago. The reported reve…
BeOne Medicines Announces Second Quarter 2026 Financial Results and Business Updates
Total global revenues of $1.7 billion for the second quarter, an increase of 30% from the prior year BRUKINSA (zanubrutinib) global revenues of $1.2 billion for the second quarter, an increase of 31% from the prior year Diluted GAAP Earnin…
Countdown to BeOne Medicines Ltd. - Sponsored ADR (ONC) Q2 Earnings: A Look at Estimates Beyond Revenue and EPS
Wall Street analysts expect BeOne Medicines Ltd. - Sponsored ADR (ONC) to post quarterly earnings of $1.40 per share in its upcoming report, which indicates a year-over-year increase of 66.7%. Revenues are expected to be $1.66 billion, up…
BeOne Medicines Expands U.S. Manufacturing with Total Investment of More Than $1 Billion to Advance Innovative Cancer Medicines
$300 million expansion of flagship manufacturing facility in Hopewell, New Jersey, adds small molecule manufacturing capacity, enhancing U.S. domestic production capabilities Creates 120 new full-time jobs to support U.S. manufacturing of…
BeOne Medicines to Announce Second Quarter 2026 Financial Results on August 5
SAN CARLOS, Calif., July 17, 2026--(BUSINESS WIRE)--BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, will report its second quarter 2026 financial results on Wednesday, August 5, 2026 before the fina…
Is BeOne Medicines AG (ONC) Stock Positioned for Growth After Encouraging ASCO Cancer Data?
We recently compiled a list of the 10 Most Promising Cancer Stocks According to Wall Street Analysts. BeOne Medicines AG (NASDAQ:ONC) is one of the most promising stocks on our list. TheFly reported on June 2 that RBC Capital analyst Leoni…
BeOne Medicines Announces Positive Phase 3 Results for BRUKINSA in Frontline Mantle Cell Lymphoma
Foundational BTKi BRUKINSA plus rituximab reduced the risk of progression or death by 43% versus bendamustine plus rituximab (HR=0.57; p<0.0001), meeting the primary endpoint of PFS MANGROVE is the first Phase 3 trial to advance a new chem…
Here is Why BeOne (ONC) One of the Most Promising Long-Term Stocks to Buy According to Analysts
BeOne Medicines (NASDAQ:ONC) is one of the most promising long-term stocks to buy according to analysts. On June 1, BeOne presented new clinical data at the 2026 ASCO Annual Meeting, highlighting accelerated progress across three high-prio…
BeOne Medicines (ONC): Citizens Sees an Inflection Point in Its Cancer Pipeline
BeOne Medicines AG (NASDAQ:ONC) is one of the most promising healthcare stocks according to Wall Street analysts. On June 3, Citizens kept its Market Outperform rating and $396 price target on BeOne Medicines AG (NASDAQ:ONC). The firm made…
BeOne Medicines (ONC) Presents Updated BRUKINSA Phase 3 Data at EHA
BeOne Medicines Ltd. (NASDAQ:ONC) is one of the high-growth large-cap stocks to invest in. On June 11, BeOne Medicines Ltd. (NASDAQ:ONC) presented updated Phase 3 clinical data at the European Hematology Association Congress for its approv…
BeOne Medicines’ Foundational Hematology Franchise Leads Next Era of B-Cell Cancer Innovation at EHA 2026
Tacabrutideg (BGB-16673, BTK degrader) showed durable responses in heavily pretreated R/R CLL and BTK inhibitor–naïve patients, signaling potential for earlier lines of treatment BRUKINSA plus sonrotoclax (ZS) delivered deep, durable respo…
BeOne Showcases Landmark Phase 3 Data in CLL Patients Aged 80+ at EHA 2026, Reinforcing BRUKINSA Benefit
Nearly two-thirds of patients aged 80+ treated with BRUKINSA remained progression-free at six years, despite advanced age and high-risk features New European patient research reveals safety, disease severity, and effectiveness are the top…
BeOne Medicines (ONC) Valuation Check After ASCO 2026 Solid Tumor Updates
Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. BeOne Medicines (ONC) is back in focus after ASCO 2026 updates on three solid tumor drugs: its CD…
BeOne Medicines Highlights Accelerating Solid Tumor Pipeline with New Data at ASCO 2026
Oral and poster presentations span three priority programs in breast, gynecologic, and gastrointestinal cancers, advancing rapidly toward pivotal development Company to host investor webcast showcasing momentum across solid tumor pipeline…
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 2026
Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapy BRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) d…
BeOne Medicines Announces Phase 3 HERIZON-GEA Data Published in NEJM and Presented at ASCO 2026
TEVIMBRA plus ZIIHERA and chemotherapy demonstrated statistically significant overall survival benefit with an unprecedented seven-month improvement in first-line HER2+ GEA Oral presentation at ASCO highlights benefit regardless of PD-L1 s…
BeOne Medicines to Present at the Goldman Sachs 47th Annual Global Healthcare Conference
SAN CARLOS, Calif., May 26, 2026--(BUSINESS WIRE)--BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced it will participate in the Goldman Sachs 47th Annual Global Healthcare Conference o…
How The BeOne Medicines (ONC) Story Is Shifting With Sonrotoclax And Brukinsa
Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. The latest analyst update on BeOne Medicines fine tunes the model fair value estimate from US$408.3…